Immunological Elimination of Undifferentiated Human Pluripotent Stem Cells Using Pluripotent State-Specific Antigen, Glypican-3Marina Okada 1, Shugo Tohyama 1, Jun Fujita 1, Tetsuya Nakatsura 2, Keiichi Fukuda 1
1Department of Cardiology, Keio University School of Medicine, 2Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Japan
Regenerative therapies using human induced pluripotent stem cells (hiPSCs) have recently attracted much attention. In this study, we use anticancer immunotherapy with peptide vaccination to prevent hiPSC-derived tumorigenesis. Our results show that glypican-3 (GPC3) works as a pluripotent state-specific immunogenic antigen in hiPSCs.
